Monoclonal antibodies 35S and 55S, specific for herpes simplex virus type 1 (HSV-1) glycoproteins gB and gD respectively, were found to react with infected cell membranes but not cell-free virions. This indicates that the spectrum of viral determinants detectable on the infected cell surface is not identical to that detectable on the virion envelope. The monoclonal antibody 35S could promote recovery from ocular HSV-1 infection in mice. Thus, antibody reactive with infective cell-specific determinants can play a significant role in host resistance to HSV-1 infection.
Recent studies have demonstrated that passive transfer of monoclonal antibodies specific for the major herpes simplex virus (HSV-1)-encoded glycoproteins (gB, gC, gD and gE) can effectively protect recipient mice against lethal HSV infection (Dix et al., 1981 ; Balachandran et al., 1982; Rector et al., 1982) . An additional observation was that monoclonal antibodies that completely lacked detectable virus-neutralizing activity in vitro could nevertheless be protective in vivo. The explanation as to how non-neutralizing antibody mediates its protective effect remains unresolved. One possibility is that monoclonal antibodies did in fact neutralize virus infectivity in vivo with the help of serum components or immunologically reactive cells not present in vitro. For example, antibody-coated viruses could have attached to macrophage Fc receptors in vivo resulting in engulfment and destruction by phagocytic cells (Leslie & Alexander, 1979) . It is also possible that antibody binding to virions may have reduced the infectivity of HSV within the host by agglutinating virus particles with a resulting net decrease in the number of infectious units (Cooper & Welsh, 1979) . In addition, virus-monoclonal antibody mixtures could have primed the cellular immune response, thus facilitating clearance of the infection (Greenspan et al., 1982) .
An alternative and perhaps more attractive hypothesis is that antibody binding at the level of the infected cell was sufficient in itself to trigger a protective response, i.e. binding of the passively transferred antibody at the level of the virion was not essential for recovery. This latter hypothesis could be tested if monoclonal antibodies were available which reacted with HSVinfected cells but not cell-free virions. Accordingly, a number of non-neutralizing monoclonal antibodies were screened for this specificity. Two have been identified, one of which can promote recovery from ocular HSV-1 infection.
The production and characterization of the monoclonal antibodies used in the present study have been described. Table 1 summarizes the specificity and isotype of each. Briefly, the three Sseries monoclonal antibodies were prepared against 14012 strain of HSV-1 (Showalter et al., 1981) while F3AB and H7E were made against the KOS strain of HSV-1 (Rector et al., 1982) .
In the initial characterization studies, it was found that none of the above monoclonal antibodies could neutralize either strain of HSV-1 in the presence or absence of complement. However, the absence of neutralization does not rule out antibody-virion interaction, because certain antibodies can form immune complexes that remain infectious. Addition of antiimmunoglobulin to such complexes can lead to virus neutralization (Ashe & Notkins, 1966; Shrivers & Daniels, 1979) .
To test for infectious antibody-virion complex formation, a 1:25 dilution of rabbit anti-mouse The monoclonal antibodies were examined for their capacity to bind to infected cells but not purified virions in an enzyme-linked immunosorbent assay (ELISA). KOS virions were purified from infected mouse embryo fibroblast (MEF) or Vero cell cytoplasmic extracts on Dextran T 10 gradients as described by Sarmiento et al. (1979) . Briefly, cells were grown in 150 cm 2 flasks, infected with HSV-1 (strain KOS) at an m.o.i, of 20 p.f.u./cell and harvested by scraping when gross cytopathic effects were observed. The cells were resuspended in 1.0 mM-sodium phosphate buffer pH 7-4, and lysed with a Dounce homogenizer. Nuclei were pelleted and cytoplasmic extracts were layered on 30 ml Dextran T 10 gradients. Gradients were centrifuged at 50 000 g in an SW, 27 rotor at 4 °C for 1 h. The opalescent band of virus in the middle of the gradient was collected and frozen in Dextran T 10 solution and stored at -70 °C. The infectivity of the preparations was determined by plaque titration on Vero cells. The preparations were examined by electron microscopy for purity from host cell membranes and damage to virions; negatively stained samples showed intact virions free of host cell debris.
The purified virions were attached to polystyrene plates pretreated with 0.001 ~ poly-L-lysine (Sigma). Approximately 1 x 106 p.f.u, in 0.1 ml were placed in test wells, while 0.1 ml dextran was substituted for virus in control wells. The plates were immediately centrifuged at 1500 g in a Beckman tabletop centrifuge for 20 rain at 4 °C. Plates were then fixed with 0.25~ glutaraldehyde in phosphate-buffered saline (PBS) and blocked with 100 mta-glycine containing 0.1 ~ bovine serum albumin followed by further blocking with 10 ~ newborn calf serum in PBS to prevent non-specific binding of antibody to plastic. In a similar manner, MEF or Vero cells infected 24 h before with KOS were attached to ELISA plates. Monoclonal antibodies in ascitic form were serially diluted tenfold beginning at a dilution of 1:100 and reacted overnight at 4 °C with the plastic-bound virions and infected cells. Binding was measured with a hybridoma screening kit (Bethesda Research Laboratories) according to the directions of the manufacturer. Absorbances of wells were measured at 414 nm using a Titertek Multiscan plate reader (Flow Laboratories). Controls for non-specific binding and sufficient antigen coating were included in each assay. Non-specific binding was measured in adjacent wells containing dextran or uninfected cells. Adequate antigen coating of wells was assessed by including monoclonal antibodies reactive with both purified virions and infected cells in each assay. The assay used was highly sensitive, detecting as little as 0,2 ng of affinity-purified antibody to specific HSV glycoproteins.
The ELISA results, presented in et al. (1982) for data. 1" Assays for antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytolysis (CDC) were carried out in microtitre plates with round-bottomed wells. In both assays, the target cells were Chang liver cells infected in monolayers 15 to 18 h previously with HSV-1 (strain KOS) at an m.o.i, of 10 p.f.u./cell. After being labelled with 200 to 300 p.Ci 5~Cr (sodium chromate; New England Nuclear) for 1 h at 37 °C, monolayers were washed three times with medium, trypsinized, and 4 x 103 target cells were put into wells in 0.1 ml volumes. Fifty ~tl of test or control ascites fluid at the desired dilution was then added, followed by 50 ~tl of effector ceils (ADCC) or complement (CDC). For the ADCC test, effector cells were human peripheral blood mononuclear cells isolated on Mono-poly resolving medium (Flow Laboratories) and adjusted to effector :target cell ratios of 100 : 1. After addition of effector cells, the plates were centrifuged at 760 g in a Beckman tabletop centrifuge for 5 min and incubated for l 8 h at 37 °C under CO2. Sample volumes of 0.1 ml were counted in a Beckman 4000 gamma counter. For the CDC assay, 50 ~tl of 1 : 10 diluted complement (Cedarlane Laboratories, Hicksville, N.Y., U.S.A.) was added and the plates were incubated for 1.5 h at 37 °C prior to determining release of SlCr. In both assays, the extent of cytolysis was calculated as follows: ~ specific lysis = [(experimental 5~Cr release -spontaneous 51Cr release)/(maximum 51Cr release -spontaneous 51Cr release)] × 100. Maximum 5 ~Cr release was determined by adding 2.5~ SDS. Spontaneous release was the counts released in the presence of medium alone.
Short communication
:~ Values represent the reciprocal of the highest antibody dilution giving 5~Cr release greater than the release obtained with mononuclear cells plus control serum at the 0.05 level of significance, as determined by Student's ttest. A minus (-) indicates no lysis at 1 : 100 dilution of antibody. Spontaneous release = 14.6~.
§ Value represents the reciprocal of the highest antibody dilution giving 51Cr release greater than the release obtained with complement alone at the 0.05 level of significance, as determined by Student's t-test. A minus (-) indicates no lysis at 1:50 dilution of antibody. Spontaneous release = 3.7~.
to bind to the surface of KOS virions. In contrast, the remaining monoclonal antibodies tested gave positive reactions in the same assay. The failure of 55S and 35S to bind to KOS virions attached to the plates could not be attributed to the type of cell in which the virus was grown because identical binding patterns of monoclonal antibodies were obtained with virions purified from either primary MEF cultures or Vero cells.
Although monoclonal antibodies 35S or 55S did not bind to KOS virions, both specifically reacted at high dilutions with KOS-infected MEF (Table l) . Binding of these two monoclonal antibodies to infected but not to uninfected MEF was confirmed in immunofluorescence tests.
Next, passive transfer experiments were conducted to determine whether infected cellspecific monoclonal antibodies could protect against HSV-1 corneal infection. BALB/c mice (20 per experiment) were challenged on the scarified right cornea with 3.9 × 107 p.f.u./ml KOS strain. Four h later, each of 10 mice received 0-3mg monoclonal antibody protein intraperitoneally. In prior passive transfer studies with other monoclonal antibodies this concentration was found to be protective (Rector et al., 1982) . All mice were then followed for survival. Monoclonal antibody 55S did not significantly (P < 0.2) protect against development of a fatal encephalitis. However, in each of two independent experiments monoclonal antibody 35S enabled six of ten recipients to survive ocular HSV-1 challenge whereas survival of the untreated controls was 0/10 and 1/10 respectively. Thus, monoclonal antibody 35S could exert a significant (P < 0.001) immunotherapeutic effect.
The lytic activities of 35S and 55S for virus-infected cells in the presence of complement (CDC) or effector cells (ADCC) was assessed (Table 2) . In these tests, G8C, a monoclonal antibody of isotype IgG2b and specific for HSV-1 glycoprotein C (Rector et al., 1982) served as a positive control. It was found that 35S could lyse KOS-infected cells in the presence of mononuclear cells but not in the presence of complement. Monoclonal antibody 55S showed no significant activity in either lytic assay.
Monoclonal antibodies have identified epitope variations among HSV antigens not previously recognized with heterologous antiserum. Pereira et al. (1981) used a panel of monoclonal antibodies to demonstrate strain-specific epitopes on HSV glycoproteins. More recently, Holland et al. (1983) selected antigenic variants of HSV with anti-HSV glycoprotein monoclonal antibodies. Certain variants appeared to differ from the wild-type virus by a single antigenic site. In the present study, monoclonal antibodies were utilized to distinguish differences in antigenic expression of two HSV glycoproteins expressed on infected cells and on virion envelopes. The results show that at least two of the four major viral glycoproteins of HSV differ in epitope expression between the virion envelope and the infected cell membrane.
There are several possible explanations for the failure of 35S and 55S to recognize viral glycoproteins on the virion envelope. First, recent analysis of the specificity of antibodyproducing cells has demonstrated that antigen recognition by B cells may be determined by both viral and H-2 antigenic determinants expressed on the surface of antigen-presenting cells (Katz et al., 1978; Gorczynski et al., 1980; Singer et al., 1981; Nisbet-Brown et al., 1981) . Thus, infected cell-specific monoclonal antibodies may be recognizing determinants expressed on glycoproteins only when they are expressed in conjunction with cell membrane components such as the major histocompatibility antigens (Wylie et al., 1982) . Alternatively, cell-specific monoclonal antibodies may be recognizing specific glycosylated forms of each glycoprotein which appear within infected cells during the glycosylation process but do not appear on the membranes of mature virions . Finally, some of the antigenic sites exposed on infected cell surfaces may become inaccessible to antibody when they are incorporated into the virion.
By utilizing infected cell-specific monoclonal antibodies in passive transfer experiments, the possibility of virus-monoclonal antibody complexes contributing to the protective effect of antibody could be circumvented. Thus, the demonstration that 35S could confer significant protection to ocularly infected mice clearly establishes that virion-antibody interaction is not essential in order to obtain protection against HSV-1 infection. While the exact mechanism by which infected cell-specific monoclonal antibodies confer protection against HSV-1 infection remains to be defined, it was shown that monoclonal antibody 35S mediated ADCC reactions but not complement-dependent cytolysis in vitro. Thus, ADCC could explain how 35S mediated protection in vivo.
Antibodies that recognize virus-specific epitopes found on infected cell membranes but not on cell-free virions have been recently described in other virus models. Specifically, Wylie & Klinman (1981) have shown that the monoclonal antibodies generated to influenza virus included antibodies capable of recognizing the viral haemagglutinin on infected cells but not on the virion envelope. Similarly, Schmaljohn et al. (1982) have identified infected cell-specific antibodies among monoclonal antibodies generated to viral glycoproteins of alphaviruses. Such antibodies on passive transfer could prevent lethal alphavirus encephalitis. Thus, our studies confirm these concepts and extend them to the herpesvirus system. Induction of infected cell-specific antibodies during viral infection has relevance to the evaluation of viral vaccines. Generally, the ability to stimulate production of neutralizing antibodies is a major criterion for evaluating the immunoprophylactic potential of an antiviral vaccine. Although neutralizing antibodies obviously contribute to host resistance, the results presented here suggest that antibodies that do not recognize cell-free virions can also contribute to the protection of the host against virus infection and should be considered in HSV vaccine evaluation. 
